Zacks Research Raises Earnings Estimates for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Zacks Research increased their Q1 2025 earnings per share estimates for shares of Editas Medicine in a research report issued on Wednesday, March 26th. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings per share of ($0.63) for the quarter, up from their previous estimate of ($0.73). The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine's Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.62) EPS and Q4 2026 earnings at ($0.60) EPS.

A number of other research firms have also recently commented on EDIT. Royal Bank of Canada reduced their price target on shares of Editas Medicine from $5.00 to $4.00 and set a "sector perform" rating for the company in a report on Friday, December 13th. Robert W. Baird reduced their target price on Editas Medicine from $10.00 to $8.00 and set an "outperform" rating for the company in a research note on Friday, December 13th. Chardan Capital reaffirmed a "neutral" rating on shares of Editas Medicine in a research note on Friday, December 13th. Barclays reduced their price objective on Editas Medicine from $5.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. lowered Editas Medicine from a "neutral" rating to an "underweight" rating in a research report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $6.83.

Remove Ads

Editas Medicine Price Performance

Shares of NASDAQ:EDIT traded down $0.06 during mid-day trading on Monday, hitting $1.12. The company had a trading volume of 1,964,305 shares, compared to its average volume of 2,548,410. Editas Medicine has a one year low of $1.11 and a one year high of $7.09. The firm has a fifty day moving average price of $1.50 and a 200 day moving average price of $2.11. The company has a market capitalization of $92.93 million, a PE ratio of -0.44 and a beta of 2.16.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.16). The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $37.17 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same quarter in the previous year, the firm posted ($0.23) earnings per share.

Institutional Investors Weigh In On Editas Medicine

A number of institutional investors have recently added to or reduced their stakes in EDIT. Intech Investment Management LLC bought a new position in shares of Editas Medicine during the 3rd quarter worth approximately $98,000. Dynamic Technology Lab Private Ltd bought a new stake in Editas Medicine during the third quarter worth $240,000. FMR LLC boosted its position in Editas Medicine by 110.7% in the third quarter. FMR LLC now owns 203,087 shares of the company's stock worth $693,000 after purchasing an additional 106,684 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Editas Medicine by 37.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 54,787 shares of the company's stock valued at $187,000 after purchasing an additional 14,888 shares during the period. Finally, Townsquare Capital LLC increased its position in shares of Editas Medicine by 169.8% during the 3rd quarter. Townsquare Capital LLC now owns 29,923 shares of the company's stock valued at $102,000 after purchasing an additional 18,831 shares during the last quarter. 71.90% of the stock is owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.